Intra-Cellular Therapies Price to Book Ratio 2013-2022 | ITCI

Historical price to book ratio values for Intra-Cellular Therapies (ITCI) over the last 10 years. The current price to book ratio for Intra-Cellular Therapies as of July 01, 2022 is 6.56.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Intra-Cellular Therapies Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2022-07-01 55.17 6.54
2022-03-31 61.19 $8.43 7.26
2021-12-31 52.34 $5.10 10.26
2021-09-30 37.28 $5.98 6.23
2021-06-30 40.82 $6.81 6.00
2021-03-31 33.93 $7.54 4.50
2020-12-31 31.80 $8.16 3.90
2020-09-30 25.66 $8.85 2.90
2020-06-30 25.67 $5.68 4.52
2020-03-31 15.37 $6.50 2.36
2019-12-31 34.31 $3.51 9.77
2019-09-30 7.47 $4.11 1.82
2019-06-30 12.98 $4.65 2.79
2019-03-31 12.18 $5.24 2.33
2018-12-31 11.39 $5.79 1.97
2018-09-30 21.70 $6.46 3.36
2018-06-30 17.67 $7.14 2.48
2018-03-31 21.05 $7.74 2.72
2017-12-31 14.48 $8.32 1.74
2017-09-30 15.78 $7.36 2.15
2017-06-30 12.42 $7.82 1.59
2017-03-31 16.25 $8.13 2.00
2016-12-31 15.09 $8.67 1.74
2016-09-30 15.24 $9.23 1.65
2016-06-30 38.82 $9.85 3.94
2016-03-31 27.80 $10.47 2.65
2015-12-31 53.79 $11.04 4.87
2015-09-30 40.04 $11.67 3.43
2015-06-30 31.95 $5.81 5.50
2015-03-31 23.88 $6.36 3.76
2014-12-31 17.65 $4.09 4.32
2014-09-30 13.71 $4.56 3.01
2014-06-30 16.86 $4.72 3.57
2014-03-31 18.18 $4.88 3.72
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.204B $0.084B
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00